222 related articles for article (PubMed ID: 10229644)
21. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.
Gordon YJ; Romanowski EG; Araullo-Cruz T
Cornea; 1994 Nov; 13(6):516-20. PubMed ID: 7842711
[TBL] [Abstract][Full Text] [Related]
22. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
23. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant.
Blot N; Schneider P; Young P; Janvresse C; Dehesdin D; Tron P; Vannier JP
Bone Marrow Transplant; 2000 Oct; 26(8):903-5. PubMed ID: 11081393
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.
Kern ER; Palmer J; Szczech G; Painter G; Hostetler KY
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):501-13. PubMed ID: 10772730
[TBL] [Abstract][Full Text] [Related]
25. Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice.
Imanidis G; Song WQ; Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1994 Jul; 11(7):1035-41. PubMed ID: 7937545
[TBL] [Abstract][Full Text] [Related]
26. Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.
Piret J; Désormeaux A; Gourde P; Juhász J; Bergeron MG
Antimicrob Agents Chemother; 2000 Jan; 44(1):30-8. PubMed ID: 10602719
[TBL] [Abstract][Full Text] [Related]
27. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis.
Kuppermann BD; Assil KK; Vuong C; Besen G; Wiley CA; De Clercq E; Bergeron-Lynn G; Connor JD; Pursley M; Munguia D; Freeman WR
J Infect Dis; 1996 Jan; 173(1):18-23. PubMed ID: 8537656
[TBL] [Abstract][Full Text] [Related]
28. Cidofovir use in acyclovir-resistant herpes infection.
Martinez CM; Luks-Golger DB
Ann Pharmacother; 1997 Dec; 31(12):1519-21. PubMed ID: 9416391
[TBL] [Abstract][Full Text] [Related]
29. Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse.
Bolger GT; Allen T; Garneau M; Lapeyre N; Liard F; Jaramillo J
Antiviral Res; 1997 Aug; 35(3):157-65. PubMed ID: 9298755
[TBL] [Abstract][Full Text] [Related]
30. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.
Neyts J; Leyssen P; Verbeken E; De Clercq E
Antimicrob Agents Chemother; 2004 Jun; 48(6):2267-73. PubMed ID: 15155231
[TBL] [Abstract][Full Text] [Related]
32. Acyclovir topical therapy of cutaneous herpes simplex virus infection in guinea pigs.
Park NH; Pavan-Langston D; McLean SL; Lass JH
Arch Dermatol; 1980 Jun; 116(6):672-5. PubMed ID: 7377804
[TBL] [Abstract][Full Text] [Related]
33. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD
Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726
[TBL] [Abstract][Full Text] [Related]
34. Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.
Flores-Aguilar M; Huang JS; Wiley CA; De Clercq E; Vuong C; Bergeron-Lynn G; Chandler B; Munguia D; Freeman WR
J Infect Dis; 1994 Mar; 169(3):642-7. PubMed ID: 8158041
[TBL] [Abstract][Full Text] [Related]
35. Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient.
Muluneh B; Dean A; Armistead P; Khan T
J Oncol Pharm Pract; 2013 Jun; 19(2):181-5. PubMed ID: 22635417
[TBL] [Abstract][Full Text] [Related]
36. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2.
Sauerbrei A; Bohn K; Heim A; Hofmann J; Weissbrich B; Schnitzler P; Hoffmann D; Zell R; Jahn G; Wutzler P; Hamprecht K
Antivir Ther; 2011; 16(8):1297-308. PubMed ID: 22155911
[TBL] [Abstract][Full Text] [Related]
37. Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.
Ellis MN; Lobe DC; Spector T
Antimicrob Agents Chemother; 1989 Oct; 33(10):1691-6. PubMed ID: 2556074
[TBL] [Abstract][Full Text] [Related]
38. Acyclovir-resistant herpes: expanded access available for cidofovir gel (Forvade).
AIDS Treat News; 1997 Feb; (No 264):5. PubMed ID: 11364104
[TBL] [Abstract][Full Text] [Related]
39. Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC.
Besen G; Flores-Aguilar M; Assil KK; Kupperman BD; Gangan P; Pursley M; Munguia D; Vuong C; De Clercq E; Bergeron-Lynn G
Arch Ophthalmol; 1995 May; 113(5):661-8. PubMed ID: 7748139
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
Smee DF; Bailey KW; Sidwell RW
Chemotherapy; 2003 Jun; 49(3):126-31. PubMed ID: 12815205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
